Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
18,670
Total Claims
$8.5M
Drug Cost
1,515
Beneficiaries
$5,586
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+42%
Cost per patient vs peers
$5,586 vs $3,933 avg
+2%
Brand preference vs peers
52.1% vs 51.2% avg
Brand vs Generic
Brand: 8,927 claims · $8.0M
Generic: 8,194 claims · $171K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 1,311 | $1.2M |
| Semaglutide | 851 | $1.2M |
| Tirzepatide | 500 | $675K |
| Insulin Glargine,hum.Rec.Anlog | 776 | $575K |
| Insulin Lispro | 429 | $448K |
| Insulin Aspart | 408 | $425K |
| Dulaglutide | 283 | $416K |
| Insulin Degludec | 370 | $285K |
| Sitagliptin Phos/Metformin Hcl | 230 | $238K |
| Insulin Lispro Protamin/Lispro | 124 | $187K |
| Insulin Lispro | 120 | $160K |
| Insulin Regular, Human | 111 | $144K |
| Dapagliflozin Propanediol | 115 | $140K |
| Insulin Aspart | 144 | $139K |
| Insulin Aspart Prot/Insuln Asp | 88 | $137K |
Prescribing Profile
Patient Profile
69
Avg Age
59%
Female
1.80
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data